Tatmyctofusp: The Core of Our Technology
Tatmyctofusp is a first-in-class recombinant fusion protein designed to deliver a transient MYC-driven signal directly into dysfunctional immune cells. The molecule consists of the Tat Protein Transduction Domain (PTD) fused to the human c-MYC protein, enabling efficient intracellular delivery without the use of viral vectors, gene editing, or receptor-dependent uptake mechanisms. Manufactured in a certified facility using an E. coli expression system, Tatmyctofusp undergoes a tightly controlled purification and refolding process that restores its native conformation and biological activity. During refolding, specialized affinity tags facilitate correct electrostatic reorganization, enabling the protein to assemble into uniform nanoparticles approximately 80–120 nm in diameter, each comprising ~200 protein molecules.
This proprietary tag-assisted protein nanoparticle architecture supports efficient cellular entry and a potent yet time-limited biological effect, enhancing immune cell function without permanent genetic modification
What makes it Tatmyctofusp unique
- Receptor-independent entry: Efficient intracellular delivery via a Tat cell-penetrating domain, enabling uptake independent of surface receptor expression that may be down-regulated in tumor settings.
- Direct nuclear programming: Delivers a transient MYC driven signal within immune cells, supporting metabolic and transcriptional programs associated with cellular activation and functional fitness.
- Downstream of IL-2: Engages intracellular pathways downstream of cytokine signaling, aiming to enhance growth and cytotoxic potential without systemic cytokine exposure.
-
Immune-cell–restricted clinical application
In clinical use, Tatmyctofusp is used ex vivo to patient-derived immune cells prior to reinfusion, limiting exposure to the intended cellular population. - Transient, non-integrating mechanism: Tatmyctofusp does not integrate into DNA or permanently modify the genome. The protein is naturally degraded within 3–5 days, resulting in a controlled and reversible biological effect.
Science Behind Tatmyctofusp
When the immune system is exposed to cancer or persistent infections, immune cells can enter a state known as “exhaustion.” Continuous antigen stimulation causes these cells to gradually lose energy, reduce proliferation, and increase expression of checkpoint receptors. While these receptors help prevent overactivation and tissue damage, they can also limit the immune system’s ability to mount effective responses against disease.
During exhaustion, intracellular metabolic pathways become suppressed, and key regulators such as MYC decline. Reduced MYC activity is associated with diminished energy production, impaired cell division, and decreased functional capacity.
Tatmyctofusp is designed to give the immune cells a sudden boost of energy by providing a transient MYC-driven signal. The recombinant protein is being explored as a platform technology with potential relevance across multiple immune cell types. The accompanying illustration demonstrates the proposed mechanism by which transient MYC signaling may improve the functional fitness of exhausted T cells.
